Home » Newsletters » The Carlat Hospital Psychiatry Report

The Carlat Hospital Psychiatry Report

Paraphilic Disorders (Oct/Nov/Dec) | 2022

View Archived Issues

Learning Objectives: Paraphilic Disorders, CHPR, Oct/Nov/Dec 2022

October 1, 2022

QT Intervals in Psychiatric Practice

October 1, 2022

Victoria Hendrick, MD and Paul Barkopoulos, MD.

Several psychiatric medications prolong the QTc interval and place patients at risk of the dreaded torsade de pointes. Some patients are particularly vulnerable to QTc prolongation: the elderly, patients with heart disease and electrolyte imbalances, and patients taking certain medications, like thioridazine and ziprasidone. We provide a step-by-step guide so that you can keep your patients safe from this cardiovascular side effect.

Paraphilic Disorders

October 1, 2022

Brian Holoyda, MD, MPH, MBA

Paraphilias, eg voyeurism and exhibitionism, are intense and recurrent sexual interests and
behaviors that involve atypical objects or activities. They become disorders when they put people at risk of harm or cause distress or impairment. Dr. Holoyda reviews the latest
treatments for these disorders and discusses approaches for working with registered sex
offenders on psychiatric units.

A Primer for Psychiatrists on Subpoenas

October 1, 2022

Ashley H. VanDercar, MD, JD.

Subpoenas can be tricky. You must balance your legal duties to comply with your obligations to your patients confidentiality. To make things even more complicated, not all subpoenas are valid. Dr. VanDercar walks us through the steps to follow when we receive a subpoena.

Who's Who? A Review of Delusional Misidentification Syndromes

October 1, 2022

Adrienne Grzenda, MD, PhD.

You have probably encountered patients who adamantly insist a loved one has been replaced by an impostor. Here are tips for how to treat them.

Smoking Cessation Intervention for Hospitalized Patients

October 1, 2022

Richard Moldawsky, MD

Richard Moldawsky, MD. Dr. Moldawsky, author for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.